Home > Keywords > Thématique > Science

Science

Articles

  • Vect-Horus Appoints Dr Jean-Manuel PEAN as Chief Scientific Officer
    3 April 2023, by Elodie DORMES

    Marseille, April 3rd, 2023 - VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer. In this role, he will lead the Company’s scientific programs and will be a member of the Management Committee of Vect-Horus.
    Alexandre Tokay, CEO and co-founder of VECT-HORUS said: "We are very pleased to have Jean-Manuel as our (…)

  • mRNA Based Therapeutics poster
    3 February 2025, by Emmanuelle BETTENDORF

    Pavlo Shpak-Kraievskyi is presenting a poster on behalf of Vect-Horus at the 4th Annual mRNA-Based Therapeutics Summit Europe, taking place January 28-30 in Frankfurt, Germany.
    Effective delivery of mRNA therapeutics to the central nervous system (CNS) remains a significant challenge due to the protective blood-brain barrier (BBB). The poster, entitled “VECTrans® Technology for CNS Targeting with Lipid Nanoparticles”, outlines results from a study of VECTrans® enabling the targeted (…)

  • Meet Vect-Horus at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit, Boston, August 21-23, 2024
    21 August 2024, by Emmanuelle BETTENDORF

    VECT-HORUS S.A.S. will be presenting a poster at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit!
    This high-profile event is taking place in Boston, MA from August 20-22, and Pavlo Shpak-Kraievskyi, Project leader, is looking forward to attending.
    Poster Title: VECTrans® Technology for CNS Targeting by Lipid Nanoparticles
    📆 Save the date: 3:30pm ET, Wednesday August 21st
    🌐 Learn More: https://ter.li/b5vw3f

  • Vect-Horus will join the Single-Domain Antibodies Summit
    14 September 2023, by Emmanuelle BETTENDORF

    Vect-Horus Vector Discovery Team will attend the Single Domain Antibodies Summit that will be held in Paris from 18th to 20th of September 2023.
    Interesting sessions are planned and Vect-Horus will attend the one dedicated to “Single domain Antibodies engineering and structure” and of course “Single domain Antibodies in neurobiology”.
    We look forward to discussing with the scientific community attending this meeting and sharing with them our last advances in the use of nanobodies as (…)

  • Vect-Horus strengthens its scientific advisory board with the appointment of Dr. Julia ALTERMAN
    22 March 2022, by Elodie DORMES

    Vect-Horus extends its Scientific Advisory Board with the expertise of Dr. Julia Alterman on siRNA chemical modification for extra-hepatic delivery.

  • Vect-Horus successfully completes the VECtoBrain project
    28 January 2019, by Jonathan NOWAK

    Ths project was supported from 2009 to 2013 by the Agence Nationale de la Recherche (ANR) BiotecS Call 2009.
    The project was coordinated by VECT-HORUS (Dr. Guillaume Jacquot) and involved the UMR7259 laboratory (CNRS and Aix-Marseille University, Director Dr Michel Khrestchatisky), the U705 laboratory (Director, Pr. Jean-Michel Scherrmann) of INSERM and the SIMOPRO laboratory (Director Dr. Vincent Dive) of the CEA.
    This project also received support (label) from the EUROBIOMED Biocluster.

  • ECMED EU-GliaPhD international conference in MALTA
    28 January 2019, by Jonathan NOWAK

    Michel Khrestchatisky and Grigorios Kyriatzis (Early Stage Researcher, ESR), both members of the ITN Marie Curie project ECMED will participate in the ECMED EU-GliaPhD international conference organized in Malta, April 29 to May 2, 2018. Michel Khrestchatisky will give a talk on the ongoing projects of his group and biotechnology partner Vect-Horus, also member of the ECMED consortium, while Grigorios Kyriatzis presented results of his ongoing PhD project.

  • Vect-Horus will participate to the event “Espace & Santé” co-organized by CNES, Region Paca and DHUNE on March 29, 2022
    28 October 2020, by Elodie DORMES

    Michel KHRESTCHATISKY will be part of the roundtable 4 and will present the company latest results in connection with “Maintaining and increasing performance – intelligent human machine interfaces, brain tech, exoskeletons, human factor, psychology… ”
    You can access to the program by following the link: https://sante-espace.com/

  • Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member
    14 November 2024, by Emmanuelle BETTENDORF

    We’re pleased to welcome Jean-Christophe Dantonel as a new member of the Vect-Horus Board of Directors!
    Dr. Dantonel brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.
    “He brings key skills to our company at an important stage of its development, with a combination of clinical research and business experience which will be invaluable as we innovate to develop vectors that facilitate targeting and delivery of (…)

  • Oligonucleotides for CNS Congress from February 22-24, 2021
    2 February 2021, by Elodie DORMES

    Dr Michel KHRESTCHATISKY will join the session dealing with “Exploring Extra-Hepatic Delivery to Relevant Targets within the CNS & Muscle” and give a talk to describe the use of VECT-HORUS “Molecular Vectors for Targeted Delivery of Oligonucleotides”.